Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 18, 2020

Primary Completion Date

November 28, 2023

Study Completion Date

November 28, 2023

Conditions
SBRTNSCLCNon-metastatic
Interventions
DRUG

GC4711 +SBRT

15 minute IV Infusion prior to SBRT

DRUG

Placebo +SBRT

15 minute IV infusion prior to SBRT

Trial Locations (10)

27710

Duke University Medical Center, Durham

29303

Gibbs Cancer Center & Research Institute, Spartanburg

31903

IACT Health, Columbus

44106

University Hospitals Cleveland Medical Center, Cleveland

52242

University of Iowa Hospitals and Clinics, Iowa City

75235

Parkland Health and Hospital System, Dallas

75390

The University of Texas Southwestern Medical Center, Dallas

80538

Banner McKee Medical Center, Loveland

80631

Banner MD Anderson Cancer Center at NCMC, Greeley

99218

Cancer Care Northwest, Spokane

Sponsors
All Listed Sponsors
lead

Galera Therapeutics, Inc.

INDUSTRY

NCT04476797 - Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC | Biotech Hunter | Biotech Hunter